ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
A Search for Helicobacter Pylori in Localized Vulvodynia

This study has been completed.

Sponsored by: Western Galilee Hospital-Nahariya
Information provided by: Western Galilee Hospital-Nahariya
ClinicalTrials.gov Identifier: NCT00501774
  Purpose

Hypothesis: to examine a possible association between localized vulvodynia and H. pylori infection.


Condition
Vulvodynia
Vulvar Vestibulitis

Drug Information available for:   Esomeprazole magnesium    Esomeprazole Sodium    Omeprazole    Omeprazole magnesium   

U.S. FDA Resources

Study Type:   Observational
Study Design:   Natural History, Cross-Sectional, Case Control, Retrospective Study
Official Title:   A Laboratory and Clinical Search for the Presence of H. Pylori and Treatment Against it in Localized Vulvodynia (Vestibulitis, Vestibulodynia).

Further study details as provided by Western Galilee Hospital-Nahariya:

Enrollment:   27
Study Start Date:   May 2004
Study Completion Date:   June 2007

Detailed Description:

Subsequent sections from the paraffin blocks were prepared and stained by modified Giemsa. Immunostaining for H. pylori was done as described. In short, tissue sections were deparaffinized in xylene, rehydrated through decreasing concentrations of alcohol ending in phosphate-buffered saline (PBS), and subjected to pretreatment with Proteinase K (8 minutes). The sections were quenched with 3% hydrogen peroxidase, incubated with protein block for 15 minutes at room temperature, and washed in PBS. Tissues then were incubated with polyclonal rabbit anti-H pylori antibody (dilution, 1:10; clone ch-20 429, DAKO, Carpinteria, CA). Finally, sections were washed in 0.05% polysorbate 20 in PBS, pH 7.4, and the bound antibody was detected using streptavidin and biotinylated secondary antibody with diaminobenzidine as the chromogen. Sections were counterstained with hematoxylin, dehydrated, and mounted. Negative controls were sections treated as above, but instead of incubation with the primary antibody, they were incubated with 1% bovine serum albumin in PBS.

Vulvar biopsies of seven other women without localized vulvodynia served as healthy controls.

The positive and negative control gastric tissues for the immunohistochemical stain of the H. pylori microorganisms were obtained from the archives of the Department of Pathology.

  Eligibility
Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Criteria

Inclusion Criteria:

  • Paraffin blocks of vestibular tissues from patients with Vestibulodynia

Exclusion Criteria:

  • Patients without vestibulodynia
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00501774

Locations
Israel
Pathology Laboratory    
      Haifa, Israel

Sponsors and Collaborators
Western Galilee Hospital-Nahariya

Investigators
Principal Investigator:     Jacob Bornstein, MD     westen Galilee Hospital    
  More Information


Publications:

Study ID Numbers:   Sabo-1
First Received:   July 13, 2007
Last Updated:   July 13, 2007
ClinicalTrials.gov Identifier:   NCT00501774
Health Authority:   Israel: Ethics Commission

Keywords provided by Western Galilee Hospital-Nahariya:
Localized vulvodynia  
Helicobacter pylori  
peptic disease  
omeprazole  

Study placed in the following topic categories:
Genital Diseases, Female
Vulvar Vestibulitis
Omeprazole
Vulvar Vestibulitis Syndrome
Vulvar Diseases

Additional relevant MeSH terms:
Vulvitis

ClinicalTrials.gov processed this record on November 04, 2008




Links to all studies - primarily for crawlers